Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer

Eitemau Tebyg

• MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
  gan: Nishiyama, Akihiro, et al.
  Cyhoeddwyd: (2020)
• In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET
  gan: Arai, Sachiko, et al.
  Cyhoeddwyd: (2017)
• Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
  gan: Wang, Rong, et al.
  Cyhoeddwyd: (2020)
• Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
  gan: Kita, Kenji, et al.
  Cyhoeddwyd: (2019)
• High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
  gan: Nanjo, Shigeki, et al.
  Cyhoeddwyd: (2015)